Form 4: Edwards Lifesciences Executive Exercises Options and Sells Shares Under 10b5-1 Plan

Daniel J. Lippis, a CVP at Edwards Lifesciences, executed stock options and sold shares under a pre-arranged 10b5-1 trading plan.

Summary

• Daniel J. Lippis, a Corporate Vice President at Edwards Lifesciences, exercised 500 employee stock options at a price of $45.2767 per share on January 16, 2025.
• Following the exercise of these options, Mr. Lippis sold 500 shares of common stock at a weighted average price of $68.7643 per share.
• These transactions were conducted under a pre-arranged Rule 10b5-1 trading plan adopted on December 11, 2023.
• The sale of shares was executed in multiple trades with prices ranging from $68.42 to $69.07.

Sentiment

Score: 5

Explanation: The document reflects a routine transaction under a pre-arranged plan, with no indication of positive or negative sentiment.

Positives

• The transactions were executed under a pre-arranged 10b5-1 trading plan, which is a common practice for executives to avoid insider trading accusations.

Risks

• Executive stock sales can sometimes be perceived negatively by the market, although this is a routine transaction under a pre-arranged plan.

Industry Context

Executive stock transactions are a common occurrence in publicly traded companies, and the use of 10b5-1 plans is a standard practice to ensure compliance with insider trading regulations.

Comparison to Industry Standards

• The use of 10b5-1 trading plans is a common practice among executives at publicly traded companies like Edwards Lifesciences, including competitors such as Medtronic and Abbott.
• These plans allow executives to sell shares in a pre-determined manner, avoiding accusations of insider trading.
• The reported transaction is consistent with typical executive compensation practices in the medical device industry.

Stakeholder Impact

• The transaction has a minimal impact on shareholders as it is a routine executive stock sale under a pre-arranged plan.

Key Dates

Keywords

insider trading, stock options, 10b5-1 plan, executive compensation, share sale, Edwards Lifesciences, EW